Cambridge, UK – Eagle Genomics (“Eagle”) is pleased to announce it has raised additional financing of £3 million (USD $4 million) with continued participation from existing investors Environmental Technologies Fund, abrdn plc, and a consortium of investors headed by Granpool Innovative Investments, to further deploy its pioneering software platform that enables corporate customers to explore and monetize on microbiome-related research. The current funding brings Eagle’s total capital raising to over £20 million (USD $25 million) over the last 12 months.

Together with this fundraising, the Company is excited to announce the appointment of Dr Victoria Kimonides as Eagle Genomics’ new CEO and Board Member. Prior to joining Eagle, Kimonides spent almost 14 years in leadership positions at Microsoft, where she spearheaded co-selling with partners and oversaw channel sales across Central and Eastern Europe. Prior to that she led Enterprise Technology Strategy and Customer & Partner Experience for the region. Kimonides has a BSc in in Biochemistry and Microbiology from King’s College London and a PhD from the University of Cambridge where she studied Neuroscience and is a leading expert in this scientific domain. She is also a Fellow of the Cambridge Judge Business School.

Additionally, Eagle is excited to announce the appointment of John Schoellerman to its Board, where he will serve as its Chair. Schoellerman is currently SVP, Corporate & Business Development at Oxford Nanopore Technologies plc, where he was instrumental in private financing, the public listing, and development of long-term strategy. Previously, Schoellerman was a Managing Director and Head of the Medical Technology practice at Lazard, the leading global investment bank.

Dr Victoria Kimonides, CEO, Eagle Genomics, said: “Eagle is a company with tremendous potential, as we can help large companies curate, analyze, and make impactful the billions of dollars being invested into microbiome research. Our goal is to help those companies commercialize that research and develop new, sustainable solutions that are good for both the people and the planet.” 

John Schoellerman, Chair, Board of Directors, Eagle Genomics, stated: “Victoria and the team have what it takes to build a category leader in the field, and I am excited to support their work with their existing blue-chip customers, and as they build out new partnerships around the world. In applying Eagle’s powerful analytical tools to life sciences data, we can gather insights today that we never could before.”

Alongside these appointments, Anthony Finbow will move to a new role of Chief Evangelist, where he will support the company in reaching its full potential and promote the importance of the exploration of the Microbiome and innovative breakthroughs in the field. Eagle would like to also acknowledge the contribution of Cliff Meltzer, who will be retiring from the Board.

Victoria Kimonides and John Schoellerman will be formally appointed to the Board at today’s Board meeting.